Literature DB >> 30964837

SHMT2 Promotes Liver Regeneration Through Glycine-activated Akt/mTOR Pathway.

Menghao Wang1, Fangchao Yuan1, He Bai1, Jie Zhang2, Hao Wu1, Kaiwen Zheng1, Wenfeng Zhang1, Mingyong Miao3, Jianping Gong1.   

Abstract

BACKGROUND: The development of liver transplantation (LT) is increasingly being limited by the unavailability of liver grafts. Unique regenerative capacity of liver in response to injuries makes living-donor liver transplantation (LDLT) a feasible strategy to meet clinical demands. Serine hydroxymethyl-transferase 2 (SHMT2) serves as the key enzyme in the biosynthesis of glycine. Glycine affects the activity of mammalian target of rapamycin (mTOR), which is important for cellular growth and proliferation. In this study, the effects of SHMT2 on mouse liver regeneration were investigated using a classical partial hepatectomy (PH) model.
METHODS: In vivo, PH was performed on mice with or without knockdown of SHMT2. In vitro, SHMT2 was overexpressed in primary hepatocytes, which were cultured in customized Dulbecco's modified eagle media and LY294002 (an Akt inhibitor). Relevant indexes of liver regeneration, cell proliferation, and Akt/mTOR signal pathways were analyzed.
RESULTS: After PH, the expression levels of SHMT2 fluctuated with time and knockdown of SHMT2 in vivo lowered the regenerative ability of liver, with reduced glycine levels compared to the scramble group. In addition, overexpression of SHMT2 in hepatocytes boosted glycine production while enhancing Akt/mTOR pathway activity. These results were validated by the application of LY294002 in vitro.
CONCLUSIONS: SHMT2 can contribute to liver regeneration after PH, and this is likely related to the activation of Akt/mTOR signaling pathway by its metabolic product, glycine, in hepatocytes. These results might have therapeutic implications for the prognosis of patients undergoing hepatic resection or transplantation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30964837     DOI: 10.1097/TP.0000000000002747

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  The role of SHMT2 in modulating lipid metabolism in hepatocytes via glycine-mediated mTOR activation.

Authors:  You-Jin Choi; Geunhye Lee; Sung Ho Yun; Wonseok Lee; Jieun Yu; Sang Kyum Kim; Byung-Hoon Lee
Journal:  Amino Acids       Date:  2022-02-25       Impact factor: 3.520

2.  SHMT2 promotes tumor growth through VEGF and MAPK signaling pathway in breast cancer.

Authors:  Shuang-Yan Xie; Ding-Bo Shi; Yi Ouyang; Fei Lin; Xiao-Yu Chen; Tong-Chao Jiang; Wen Xia; Ling Guo; Huan-Xin Lin
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

3.  Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma.

Authors:  Rachael A Clark; Jingbo Qiao; Jillian C Jacobson; Dai H Chung
Journal:  Oncotarget       Date:  2022-01-06

Review 4.  Glycinergic Signaling in Macrophages and Its Application in Macrophage-Associated Diseases.

Authors:  Zhending Gan; Meiyu Zhang; Donghui Xie; Xiaoyan Wu; Changming Hong; Jian Fu; Lijuan Fan; Shengyi Wang; Sufang Han
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

Review 5.  Serine hydroxymethyltransferase 2: a novel target for human cancer therapy.

Authors:  Min Xie; Dong-Sheng Pei
Journal:  Invest New Drugs       Date:  2021-07-03       Impact factor: 3.850

6.  Overexpression of SHMT2 Predicts a Poor Prognosis and Promotes Tumor Cell Growth in Bladder Cancer.

Authors:  Peng Zhang; Qian Yang
Journal:  Front Genet       Date:  2021-06-04       Impact factor: 4.599

Review 7.  Roles of Mitochondrial Serine Hydroxymethyltransferase 2 (SHMT2) in Human Carcinogenesis.

Authors:  Yuanyuan Zeng; Jie Zhang; Mengmeng Xu; Fuxian Chen; Ruidong Zi; Jicheng Yue; Yanan Zhang; Nannan Chen; Y Eugene Chin
Journal:  J Cancer       Date:  2021-08-08       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.